These findings collectively offer possible explanations for the promising outcomes observed in the phase 2 study, in which highly active RA patients were treated with peresolimab a humanized IgG1 monoclonal antibody stimulating the function of PD-1 (37). Here, PDCD1 is linked to rheumatoid arthritis.